{"entity":{"id":"rec-1245","kind":"drug","name":"REC-1245","aka":[],"tldr":"REC-1245 is an experimental protein degrader from Recursion Pharmaceuticals, in phase 1 trials for solid tumours and lymphoma.","summary":"REC-1245 is a protein degrader (small molecule) from Recursion Pharmaceuticals. A highly potent RBM39 degrader; the company describes RBM39 as a DNA damage response target whose loss mimics CDK12 loss. Its furthest stage is phase 1, for solid tumours and lymphoma. ClinicalTrials.gov registers it in one study linked below. Pipeline page: 'Status: Phase 1'; phase 1 DAHLIA study ongoing. Registry NCT06678659 (phase 1/2) recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Recursion Pharmaceuticals: recursion.com","url":"https://www.recursion.com/pipeline"},{"label":"Recursion Pharmaceuticals: recursion.com","url":"https://www.recursion.com/pipeline"},{"label":"ClinicalTrials.gov: trials of REC-1245","url":"https://clinicaltrials.gov/search?intr=REC-1245"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["rbm39"],"drugs":[],"companies":["recursion"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06678659"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"REC-1245","modality":"Protein degrader (small molecule)","mechanism":"A highly potent RBM39 degrader; the company describes RBM39 as a DNA damage response target whose loss mimics CDK12 loss.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rec-1245/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"rbm39","kind":"target","name":"RBM39","route":"/targets/rbm39/"}],"company":[{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/"}],"trial":[{"id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/"}]}}